Supplementary Table 10. Positivity, Median and Interquartile range [IQR] for anti-spike IgG, IgM, and IgA (data presented in Figure 6).

	t2 (N=126)	t3 (N=126)	t4 (N=126)	*p*-value* t2 vs t3	*p*-value* t2 vs t4	*p*-value* t3 vs t4
anti-spike IgG						
positive, n (%)	116 (92.06)	97 (76.98)	87 (69.05)	0.0017	8.32×10^{-6}	0.2015
ODnorm, median [IQR]	2.03 [1.69-2.21]	1.49 [1.08-1.79]	1.28 [0.84-1.58]	$<2 \times 10^{-16}$	$<2 \times 10^{-16}$	$<2 \times 10^{-16}$
anti-spike IgM						
positive, n (%)	34 (26.98)	7 (5.56)	5 (3.97)	1.365×10^{-5}	3.23×10^{-6}	0.7674
ODnorm, median [IQR]	0.65 [0.43-1.04]	0.34 [0.26-0.56]	0.36 [0.27-0.54]	$<2 \times 10^{-16}$	$<2 \times 10^{-16}$	0.7500
anti-spike IgA						
positive, n (%)	106 (84.13)	46 (36.51)	42 (33.33)	4.55×10^{-14}	2.27×10^{-15}	0.6918
ODnorm, median [IQR]	1.21 [1.08-1.62]	0.76 [0.52-1.17]	0.78 [0.53-1.08]	$<2 \times 10^{-16}$	$<2 \times 10^{-16}$	0.4100

N, total number of individuals; n, number of individuals with a given event; IQR, interquartile range; t2 – sera collected 42 days post-1st vaccine dose; t3 - sera collected ~140 days post-1st vaccine dose; t4 - sera collected 180 days post-1st vaccine dose. Quade test for differences in anti-spike IgG, IgM, and IgA levels over time, $p<2 \times 10^{-16}$.

*Statistical tests were applied according to the type of variable (Chi-square for positivity and pairwise Wilcoxon signed-rank test for ODnorm).